Buscar Company and Terramer, Inc. Advance Hemp Bioplastics to Combat Microplastic Pollution
BEVERLY HILLS, CA, CA, UNITED STATES, July 3, 2025 / EINPresswire.com / -- Buscar Company (OTC: CGLD), a diversified holding company focused on sustainable energy and natural resources, today affirms its commitment to addressing the global microplastic pollution crisis through its April 11, 2025, acquisition of a 50% stake in Terramer, Inc., a leader in hemp-based bioplastics, via a strategic stock-swap transaction. This partnership advances scalable, biodegradable solutions to protect ecosystems and public health, aligning with environmental priorities championed by advocates like Minister Robert F. Kennedy Jr. However, Buscar is not directly collaborating with the U.S. government.
Addressing a Global Crisis
Microplastic pollution poses a severe threat to ecosystems and human health. According to a 2023 UN Environment Programme report, approximately 1.2 million metric tons of microplastics enter the oceans annually from sources such as tire wear and synthetic textiles. A 2024 study by the University of California, San Diego, estimates that individuals ingest up to 200,000 microplastic particles per year through food and water, with potential links to health risks, including inflammation and antibiotic resistance.
'Hemp bioplastics offer a sustainable path to reduce microplastic pollution,' said Alexander Dekhtyar, CEO of Buscar Company. 'Our partnership with Terramer positions us to deliver innovative solutions that protect our planet and communities.'
A Strategic Partnership
Buscar's investment in Terramer accelerates the development of TERBO-1000, a hemp-based bioplastic that biodegrades within 180 days, according to ASTM D6400 standards, leaving no microplastic residue. Unlike petroleum-based plastics, which can last for centuries, TERBO-1000 is free of harmful additives like BPA and is suitable for packaging, food service, and industrial uses. The partnership aims to increase production and target key markets by 2026, harnessing hemp's low-water, carbon-sequestering properties.
'Terramer's technology is a game-changer for sustainable materials,' said Alex Mond, Chairman and Founder of Terramer, Inc. 'Together with Buscar, we're driving innovation to combat microplastic pollution.'
Strategically Positioned for Generating Revenue
Terramer Inc. has achieved significant market traction with a strong portfolio of purchase orders and letters of intent, reflecting growing demand for its innovative TERBO-1000™️ hemp-based bioplastic products. Current purchase orders include a $6,000,000 agreement with a California-based apparel brand for hemp-based parchment papers, a $621,000 order from a national packaging distributor for food containers, a $248,000 order from an Ohio-based distribution facility for additional food containers, an order from an industrial services provider for 10,000 T-shirt bags (12'x7'x22'), and a $138,000 order from a supply company for 9x9 all-black hinged clamshell containers. Additionally, Terramer has secured letters of intent, including one with a sales group for food packaging materials valued up to $80,000,000, another with the same California apparel brand for hemp-based textiles, and a third with a global quick-service restaurant chain for assorted food packaging solutions. These commitments highlight Terramer's expanding presence in the sustainable packaging and textiles markets, positioning it to capitalize on the rapidly growing bioplastics industry.
Aligned with Environmental Goals
The partnership between Buscar and Terramer advances the urgent demand for eco-friendly alternatives, targeting the replacement of a significant portion of the US$185.82–226.29 billion global single-use plastics market, including US$33.03–33.48 billion in the U.S., used in food packaging, restaurants, consumer goods, and agricultural films. Their innovative hemp bioplastic products aim to replace conventional plastics in these applications, aligning with global efforts to combat plastic pollution through enhanced recycling systems and bans on harmful plastics.
Robert F. Kennedy Jr., U.S. Secretary of Health and Human Services, emphasized during his speech at the Chemicals of Concern Policy Summit: 'Microplastics from food and food production assembly lines and packaging don't only end up on our food, they also contaminate our soil, our water, our oceans, and from there they re-enter the food supply!'
Commitment to Sustainability
Buscar and Terramer are dedicated to reducing microplastic pollution through innovative, hemp-based solutions. By advancing TERBO-1000, this partnership paves the way for a sustainable economy that prioritizes environmental and public health.
About Buscar Company
Buscar Company (OTC: CGLD) is a diversified holding firm focused on natural resources, sustainable technologies, and pharmaceuticals. Based in Beverly Hills, California, Buscar manages Eon Discovery Inc., which handles gold mining operations in California's Plumas National Forest; Terramer Inc., a leader in hemp-based biodegradable bioplastics; and Armorgenix, a pharmaceutical innovator specializing in detoxification and antiviral solutions. Formed through a strategic evolution, including a 2020 reverse merger with Eon Discovery, Buscar aims to drive growth and increase shareholder value through innovation and diversification.
Forward-Looking Statement
This press release contains forward-looking statements under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include, but are not limited to, projections about the growth of the hemp bioplastics market, the expected impact of the Buscar-Terramer partnership, and the development and commercialization of TERBO-1000. Such statements are based on current expectations and assumptions. They are subject to risks and uncertainties, including regulatory challenges, market acceptance, production delays, and economic conditions, which could cause actual results to differ significantly from these projections. Buscar makes no obligation to update these statements except as required by law. For a detailed discussion of risks, please refer to Buscar's filings with the Securities and Exchange Commission.
Alexander Dekhtyar
Buscar Company, CEO
Alexander Dekhtyar
Buscar Company
+1 833-539-4777
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
15 hours ago
- Associated Press
Buscar Company and Terramer, Inc. Advance Hemp Bioplastics to Combat Microplastic Pollution
Buscar Company (OTCMKTS:CGLD) BEVERLY HILLS, CA, CA, UNITED STATES, July 3, 2025 / / -- Buscar Company (OTC: CGLD), a diversified holding company focused on sustainable energy and natural resources, today affirms its commitment to addressing the global microplastic pollution crisis through its April 11, 2025, acquisition of a 50% stake in Terramer, Inc., a leader in hemp-based bioplastics, via a strategic stock-swap transaction. This partnership advances scalable, biodegradable solutions to protect ecosystems and public health, aligning with environmental priorities championed by advocates like Minister Robert F. Kennedy Jr. However, Buscar is not directly collaborating with the U.S. government. Addressing a Global Crisis Microplastic pollution poses a severe threat to ecosystems and human health. According to a 2023 UN Environment Programme report, approximately 1.2 million metric tons of microplastics enter the oceans annually from sources such as tire wear and synthetic textiles. A 2024 study by the University of California, San Diego, estimates that individuals ingest up to 200,000 microplastic particles per year through food and water, with potential links to health risks, including inflammation and antibiotic resistance. 'Hemp bioplastics offer a sustainable path to reduce microplastic pollution,' said Alexander Dekhtyar, CEO of Buscar Company. 'Our partnership with Terramer positions us to deliver innovative solutions that protect our planet and communities.' A Strategic Partnership Buscar's investment in Terramer accelerates the development of TERBO-1000, a hemp-based bioplastic that biodegrades within 180 days, according to ASTM D6400 standards, leaving no microplastic residue. Unlike petroleum-based plastics, which can last for centuries, TERBO-1000 is free of harmful additives like BPA and is suitable for packaging, food service, and industrial uses. The partnership aims to increase production and target key markets by 2026, harnessing hemp's low-water, carbon-sequestering properties. 'Terramer's technology is a game-changer for sustainable materials,' said Alex Mond, Chairman and Founder of Terramer, Inc. 'Together with Buscar, we're driving innovation to combat microplastic pollution.' Strategically Positioned for Generating Revenue Terramer Inc. has achieved significant market traction with a strong portfolio of purchase orders and letters of intent, reflecting growing demand for its innovative TERBO-1000™️ hemp-based bioplastic products. Current purchase orders include a $6,000,000 agreement with a California-based apparel brand for hemp-based parchment papers, a $621,000 order from a national packaging distributor for food containers, a $248,000 order from an Ohio-based distribution facility for additional food containers, an order from an industrial services provider for 10,000 T-shirt bags (12'x7'x22'), and a $138,000 order from a supply company for 9x9 all-black hinged clamshell containers. Additionally, Terramer has secured letters of intent, including one with a sales group for food packaging materials valued up to $80,000,000, another with the same California apparel brand for hemp-based textiles, and a third with a global quick-service restaurant chain for assorted food packaging solutions. These commitments highlight Terramer's expanding presence in the sustainable packaging and textiles markets, positioning it to capitalize on the rapidly growing bioplastics industry. Aligned with Environmental Goals The partnership between Buscar and Terramer advances the urgent demand for eco-friendly alternatives, targeting the replacement of a significant portion of the US$185.82–226.29 billion global single-use plastics market, including US$33.03–33.48 billion in the U.S., used in food packaging, restaurants, consumer goods, and agricultural films. Their innovative hemp bioplastic products aim to replace conventional plastics in these applications, aligning with global efforts to combat plastic pollution through enhanced recycling systems and bans on harmful plastics. Robert F. Kennedy Jr., U.S. Secretary of Health and Human Services, emphasized during his speech at the Chemicals of Concern Policy Summit: 'Microplastics from food and food production assembly lines and packaging don't only end up on our food, they also contaminate our soil, our water, our oceans, and from there they re-enter the food supply!' Commitment to Sustainability Buscar and Terramer are dedicated to reducing microplastic pollution through innovative, hemp-based solutions. By advancing TERBO-1000, this partnership paves the way for a sustainable economy that prioritizes environmental and public health. About Buscar Company Buscar Company (OTC: CGLD) is a diversified holding firm focused on natural resources, sustainable technologies, and pharmaceuticals. Based in Beverly Hills, California, Buscar manages Eon Discovery Inc., which handles gold mining operations in California's Plumas National Forest; Terramer Inc., a leader in hemp-based biodegradable bioplastics; and Armorgenix, a pharmaceutical innovator specializing in detoxification and antiviral solutions. Formed through a strategic evolution, including a 2020 reverse merger with Eon Discovery, Buscar aims to drive growth and increase shareholder value through innovation and diversification. Forward-Looking Statement This press release contains forward-looking statements under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include, but are not limited to, projections about the growth of the hemp bioplastics market, the expected impact of the Buscar-Terramer partnership, and the development and commercialization of TERBO-1000. Such statements are based on current expectations and assumptions. They are subject to risks and uncertainties, including regulatory challenges, market acceptance, production delays, and economic conditions, which could cause actual results to differ significantly from these projections. Buscar makes no obligation to update these statements except as required by law. For a detailed discussion of risks, please refer to Buscar's filings with the Securities and Exchange Commission. Alexander Dekhtyar Buscar Company, CEO Alexander Dekhtyar Buscar Company +1 833-539-4777 email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Forbes
15 hours ago
- Forbes
Trump Plan To Lower U.S. Drug Prices To Overseas Levels Lacks Details
President Donald Trump, accompanied by Health and Human Services Secretary Robert F. Kennedy Jr., ... More holds up an executive order aimed at reducing the cost of prescription pharmaceuticals during an event in the Roosevelt Room of the White House on May 12, 2025, in Washington, DC. The plan would tie U.S. drug prices to the ones paid in comparably wealthy foreign nations. (Photo by) Since President Trump issued an executive order in May that he claimed would lower prescription drug prices in the United States 'almost immediately by 30% to 80%," the administration has released no details regarding how the 'most favored nation' plan would be implemented. Such particulars may never emerge and without them a most favored nation model is likely a non-starter. The president's order aspires to implement a model known as most favored nation that ties the prices of prescription medicines in the U.S. to the lowest found among comparably wealthy nations. But even pharmaceutical executives, who represent the stakeholder most affected by the order, say the administration hasn't yet furnished them with details. At a Goldman Sachs Global Healthcare Conference last month, several pharmaceutical company executives noted a lack of clarity from the Trump administration as to how the program would be implemented. The only thing that's been made public about the most favored nation model is that the lowest price will be selected among comparably wealthy nations with at least 60% of the U.S. gross domestic product per capita. Specifically, according to a press release issued by the White House in late May, President Trump expects drug manufacturers to commit to 'aligning the prices of branded products' with the 'lowest price of a set of economic peer countries.' However, this only indicates who the comparator nations are. It doesn't list actual most favored nation price targets, which the executive order had promised HHS Secretary Robert F. Kennedy Jr. would 'communicate to pharmaceutical manufacturers to bring prices for American patients in line with comparably developed nations.' It also doesn't say whether calculations would account for differences in purchasing power between nations, not just GDP per capita. For a meaningful comparison, one needs to know how much a country's currency can buy in terms of goods and services. If not the federal government, then perhaps drug companies themselves could calculate the price targets. But this raises questions about which types of prices they'd use, publicly available list or proprietary net prices. If the latter, it's unclear whether this would violate contractual obligations. And it gets much more complicated for pharmaceutical firms. In calculating prescription drug price comparisons, simply computing the differences between prices isn't sufficient. Utilization disparities between nations must be weighted to yield an accurate, commensurate calculation. And differences in dosing and formulation must be accounted for. Since the executive order is to apply to branded medicines that do not currently have generic or biosimilar competition, it's unknown what to do if a particular drug doesn't have such competition in the U.S. but has generic or biosimilar competition in the most favored nation. This is a typical phenomenon among relatively high-cost biologics like the rheumatoid arthritis drug, Enbrel, and its referenced biosimilars which have been on the market across Europe for years and yet won't be in the U.S. until the end of this decade. Finally, the substantial differences in timing of approvals and launches of prescription drugs across countries make it hard if not impossible to create an international price index. Many recently approved branded medicines in the U.S. haven't yet been approved in other peer countries, let alone had their price determined by a government authority. The executive order's lack of details extends to the direct-to-consumer platform that it says would be established, through which American patients could buy their drugs directly from manufacturers who sell to Americans at the most favored nation price. HHS Secretary Kennedy was instructed to assist in creating such a mechanism. But how this would work remains a mystery to executives in the industry. Moreover, most drug companies aren't accustomed to selling their products directly to patients. And so, it would be quite an endeavor to build a platform from scratch. In the executive order, the president says that following the calculation of target prices, if drug companies don't doesn't voluntarily reduce prices the administration would 'propose a rulemaking plan to impose most-favored-nation pricing.' But the document doesn't disclose how—through which policy vehicle—the administration intends to pursue a rulemaking plan. One possibility is pursuit of a so-called demonstration project in the Medicare program. The executive branch has broad latitude to set up demonstration or pilot projects as it sees fit, under the authority granted the Center for Medicare and Medicaid Innovation by the Affordable Care Act. Here, CMMI's purpose is to test novel payment methods as well as care models, with the dual aim of lowering healthcare costs and improving the quality of care delivered to patients. But past experience shows the considerable limitations to what CMMI has been able to accomplish. There have been dozens of models proposed since the founding of CMMI. However, some of the proposed models, including ones on international price referencing, never got tested. And the majority of models that did get implemented failed to yield cost savings. Indeed, thus far only two have been made a permanent part of a public program: A diabetes and an accountable care organization demonstration project became permanent fixtures in Medicare. Most models ultimately get canceled, including recently a value-based insurance design initiative in Medicare Advantage. There are also logistical questions around the pursuit of a CMMI model for most favored nation drug pricing that need to be clarified. Would it be a voluntary or mandatory model? Until now, the vast majority of CMMI projects have been voluntary. The question becomes would healthcare providers in the so-called buy-and-bill space want to volunteer to participate in a system in which they potentially could get reimbursed less than the price at which they purchased products. If a most favored nation demonstration project were to be mandatory, this could lead to court challenges from physician groups in addition to the pharmaceutical industry. And then there's the issue of what the timeframe would be. Originally, the first Trump administration laid out a five-year period of gradual conversion towards an international price index that constituted a blend of U.S. and overseas prices. It appears that the second administration is far less patient and wants to achieve results as soon as possible. In announcing the most favored nation plan, President Trump posted on his social media platform in May that the prices of prescription medicines would fall "almost immediately" from 30% to 80% off of their current levels. But at this point in time, it's unknown how this would be achieved and whether the logistical and legal challenges could be overcome.
Yahoo
15 hours ago
- Yahoo
Here's Lindsell Train Global Equity Fund's Comment on Nintendo Co., Ltd. (NTDOY)
Lindsell Train Ltd, an investment management company, has released its "Lindsell Train Global Equity Fund" first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The objective of the fund is to boost long-term Shareholders' capital from an actively managed global equity portfolio, mainly on recognized exchanges in developed countries worldwide. The fund returned -2.0% in the quarter, outperforming the -4.7% return for the benchmark MSCI World Index. In addition, you can check the top 5 holdings of the fund to know its best picks in 2025. In its first-quarter 2025 investor letter, Lindsell Train Global Equity Fund highlighted stocks such as Nintendo Co., Ltd. (OTC:NTDOY). Nintendo Co., Ltd. (OTC:NTDOY) is a video game company that develops, manufactures, and sells home entertainment products. The one-month return of Nintendo Co., Ltd. (OTC:NTDOY) was 8.77%, and its shares gained 66.08% of their value over the last 52 weeks. On July 2, 2025, Nintendo Co., Ltd. (OTC:NTDOY) stock closed at $22.82 per share, with a market capitalization of $106.133 billion. Lindsell Train Global Equity Fund stated the following regarding Nintendo Co., Ltd. (OTC:NTDOY) in its Q1 2025 investor letter: "The cause of Nintendo Co., Ltd.'s (OTC:NTDOY) exuberant performance has of course been the build up to, and now the ultimate reveal of the Switch 2, its much-anticipated new flagship console. A number of aspects from the launch provide continued cause for optimism. Pricing for both the console and Nintendo's first-party games was robust, and at the higher end of estimates, demonstrating the clear confidence the company has in the quality of its latest product offerings. There was an impressive line-up of third-party titles (Elden Ring, Cyberpunk 2077, Hogwart's Legacy, Civilization VII), which should broaden consumer appeal further. Plus, a number of compelling new functionalities were introduced that will require a Nintendo Online subscription, which represents a healthy way for Nintendo to convert an increasing percentage of its consumer base to a more intimate relationship, with more data sharing, and regular subscription fees. We look forward to further incremental updates and reveals throughout the year in the lead up to the launch day, and beyond that, the all important year-end holiday season." A close up of a person's hands using a home console gaming device. Nintendo Co., Ltd. (OTC:NTDOY) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 1 hedge fund portfolios held Nintendo Co., Ltd. (OTC:NTDOY) at the end of the first quarter, which was 1 in the previous quarter. While we acknowledge the potential of Nintendo Co., Ltd. (OTC:NTDOY) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of NTDOY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
